Therapeutic Effects of Cannabinoids and Their Applications in COVID-19 Treatment

Primer Autor
Paz, Cristian
Co-autores
Perez, Rebeca
Glaser, Talita
Villegas, Cecilia
Burgos, Viviana
Ulrich, Henning
Título
Therapeutic Effects of Cannabinoids and Their Applications in COVID-19 Treatment
Editorial
MDPI
Revista
LIFE-BASEL
Lenguaje
en
Resumen
Cannabis sativa is one of the first medicinal plants used by humans. Its medical use remains controversial because it is a psychotropic drug whose use has been banned. Recently, however, some countries have approved its use, including for recreational and medical purposes, and have allowed the scientific study of its compounds. Cannabis is characterized by the production of special types of natural products called phytocannabinoids that are synthesized exclusively by this genus. Phytocannabinoids and endocannabinoids are chemically different, but both pharmacologically modulate CB1, CB2, GRP55, GRP119 and TRPV1 receptor activities, involving activities such as memory, sleep, mood, appetite and motor regulation, pain sensation, neuroinflammation, neurogenesis and apoptosis. Delta 9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are phytocannabinoids with greater pharmacological potential, including anti-inflammatory, neuroprotective and anticonvulsant activities. Cannabidiol is showing promising results for the treatment of COVID-19, due to its capability of acting on the unleashed cytokine storm, on the proteins necessary for both virus entry and replication and on the neurological consequences of patients who have been infected by the virus. Here, we summarize the latest knowledge regarding the advantages of using cannabinoids in the treatment of COVID-19.
Fecha Publicación
2022
Tipo de Recurso
artículo de revisión
doi
10.3390/life12122117
Formato Recurso
PDF
Palabras Claves
refractory epilepsy
COVID-19
phytocannabinoids
synthetic cannabinoids
clinical trials
Ubicación del archivo
http://dx.doi.org/10.3390/life12122117
Categoría OCDE
Ciencias biológicas y biomedicina: otros temas
Microbiología
Biotecnología Médica
Farmacología y Farmacia
Materias
epilepsia refractaria
COVID-19
fitocannabinoides
cannabinoides sintéticos
ensayos clínicos
Identificador del recurso (Mandatado-único)
artículo de revisión
Versión del recurso (Recomendado-único)
versión publicada
License
CC BY 4.0
Condición de la licencia (Recomendado-repetible)
CC BY 4.0
Derechos de acceso
acceso abierto
Access Rights
acceso abierto
Id de Web of Science
WOS:000902365700001
Tipo de ruta
verde# dorado
Categoría WOS
Ciencias biológicas y biomedicina: otros temas
Microbiología
Referencia del Financiador (Mandatado si es aplicable-repetible)
FAPESP 2018/07366-4
ANID 201808426-0
CNPq 406396/2021-3
USP-PIPAE
Colecciones
Colección Publicaciones Científicas
Colección ANID
Revisa las metricas alternativas de Almetrics
Revisa las citaciones de Dimensions